Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
428 Views
Emedinexus 07 April 2025
Vanrafia received accelerated FDA approval based on a pre-specified interim analysis from the Phase III ALIGN study, demonstrating a reduction in proteinuria at 36 weeks compared to placebo.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}